Your browser doesn't support javascript.
loading
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Gao, Sizhi P; Chang, Qing; Mao, Ninghui; Daly, Laura A; Vogel, Robert; Chan, Tyler; Liu, Shu Hui; Bournazou, Eirini; Schori, Erez; Zhang, Haiying; Brewer, Monica Red; Pao, William; Morris, Luc; Ladanyi, Marc; Arcila, Maria; Manova-Todorova, Katia; de Stanchina, Elisa; Norton, Larry; Levine, Ross L; Altan-Bonnet, Gregoire; Solit, David; Zinda, Michael; Huszar, Dennis; Lyden, David; Bromberg, Jacqueline F.
Afiliación
  • Gao SP; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Chang Q; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Mao N; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Daly LA; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Vogel R; Computational Biology Program, MSKCC, New York, NY 10065, USA.
  • Chan T; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Liu SH; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Bournazou E; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Schori E; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.
  • Zhang H; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, Cell and Developmental Biology, Weill Cornell Medical College (WCMC), New York, NY 10021, USA.
  • Brewer MR; Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA. Personalized Cancer Medicine, VICC, Nashville, TN 37232, USA.
  • Pao W; Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center (VICC), Nashville, TN 37232, USA. Personalized Cancer Medicine, VICC, Nashville, TN 37232, USA.
  • Morris L; Department of Surgery, MSKCC, New York, NY 10065, USA.
  • Ladanyi M; Department of Pathology, MSKCC, New York, NY 10065, USA. Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA.
  • Arcila M; Department of Pathology, MSKCC, New York, NY 10065, USA.
  • Manova-Todorova K; Molecular Cytology, MSKCC, New York, NY 10065, USA.
  • de Stanchina E; Antitumor Assessment, MSKCC, New York, NY 10065, USA.
  • Norton L; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. WCMC, New York, NY 10021, USA.
  • Levine RL; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA. WCMC, New York, NY 10021, USA.
  • Altan-Bonnet G; Computational Biology Program, MSKCC, New York, NY 10065, USA.
  • Solit D; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA. WCMC, New York, NY 10021, USA. Metastasis Research Center, MSKCC, New York, NY 10065, USA.
  • Zinda M; Oncology iMED, AstraZeneca, Waltham, MA 02451, USA.
  • Huszar D; Oncology iMED, AstraZeneca, Waltham, MA 02451, USA.
  • Lyden D; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics, Cell and Developmental Biology, Weill Cornell Medical College (WCMC), New York, NY 10021, USA. Department of Pediatrics, MSKCC, New York, NY 10065, USA. Drukier Institute for Children's Health, Meyer Cancer Center, WCMC,
  • Bromberg JF; Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. WCMC, New York, NY 10021, USA. dcl2001@med.cornell.edu bromberj@mskcc.org.
Sci Signal ; 9(421): ra33, 2016 Mar 29.
Article en En | MEDLINE | ID: mdl-27025877
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Janus Quinasa 2 / Receptores ErbB / Neoplasias Pulmonares / Mutación Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Sci Signal Asunto de la revista: CIENCIA / FISIOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Janus Quinasa 2 / Receptores ErbB / Neoplasias Pulmonares / Mutación Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Sci Signal Asunto de la revista: CIENCIA / FISIOLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos